Buy Anti-Human CD64/FCGR1A Antibody (MDX-33)

Catalog No.

FHC93420

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Applications

FCM

Target

IgG Fc receptor I, High affinity immunoglobulin gamma Fc receptor I, FcRI, FCGR1A, FCG1, FcgammaRIa, IGFR1, CD64, Fc-gamma RI, FCGR1, Fc-gamma RIA

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P12314

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.09% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

MDX-33

Note

For research use only.

Flow-cytometry

Flow-cytometry using anti-human CD64 antibody.CD64 Transfected CHO cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human CD64 antibody monoclonal antibody (Catalog # FHC93420 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # PHB96441) and cells analysed on a NovoCyte Flow Cytometer.
Bioactivity

c. Blocking of ligand (hIgG1) on Ba/F3-FcγRI (solid lines) and EL4-FcγRI (dashed lines) cells with different anti-FcγRI antibodies; 197 (circle, dark green), 10.1 (upside down triangle, blue), m22 (triangle, green), H22 (hexagon, green), and mIgG2c (square, yellow). Percentage (%) ligand blocking was calculated using the ligand only as a control.
Data sourced from citation (PMID: 41258113)
Flow Cytometry

(K) Flow cytometry analysis of ligand (i.e. hIgG1) blocking by anti-hFcγRI antibodies on EL4-hFcγRI cells. One-way ANOVA, with Tukey multiple comparison test, significance: # compared to 197, $ to H22, † to H22FcX and * to C09, N = 3-4. (L) Superoxide release by IFN-γ stimulated neutrophils from healthy donors upon antibody addition. Luminol-based chemiluminescence assay, measured in 40 second intervals. For each antibody, 3-7 donors were tested in triplicate. PBS was used for background signal. RLU = relative light units. (M) Superoxide release upon crosslinking anti-mouse or anti-human IgG (1:100 dilution) addition. For each antibody, 3-7 donors were tested in triplicate. PBS was used for background signal. (N) Quantification of area under the curve (A.U.C) for superoxide production as measured in (M). Each individual data point represents the A.U.C of one donor measured in triplicate. Ordinary one-way ANOVA, with Tukey multiple comparison test, significance like in (H-J) but * compared to clone 197, and $ compared to H22.
Data sourced from citation (PMID: 41146600)
Bioactivity

b. Binding titration of anti-FcγRI antibodies to Ba/F3-FcγRI(solidlines) and EL4-FcγRI(dashed lines) cells. Mean fluorescenceintensity(MFI) is depicted of at least N=3.
Data sourced from citation (PMID: 41258113)
Flow Cytometry

Binding of antibodies to hFcγRI and chimeric FcγRI domain swapped receptors on EL4 cells. (A) Binding of anti-hFcγRI antibodies, hIgG1 and isotype control mIgG2a to hFcγRI, and chimeras. Replaced one hEC with mEC1, mEC2, or mEC3 to verify to which domain the antibodies bind. Three independent experiments were done (measured in duplicate), and graphs for one representative experiment are shown. (B) Heatmap showing binding patterns of antibodies to hFcγRI and chimeras. To compare binding across chimeric constructs, MFI at a single antibody concentration (10 μg/mL) was used. Because MFI ranges differ between constructs due to variable receptor expression, an MFI cut-off of 5000 was applied, to enable visualization of low-level Fab-mediated interactions while avoiding confounding by variation at the higher end of the MFI range. All dark green boxes have an MFI >5000. (C) Fold change of antibody binding normalized to isotype control was calculated from MFI at 10 μg/mL. MFI was used instead of EC50 as many constructs show little or no binding, making curve fitting unreliable. Two-way ANOVA, with Tukey's post hoc test for multiple comparisons. *significance compared to isotype control. *p <0.05, **p <0.01, ***p <0.001, and ****p <0.0001, N = 2-3 per experiment. H22 is humanized version of m22 and FcX is Fc silent version of H22.
Data sourced from citation (PMID: 41146600)
Bioactivity

m. Area under the curve (AUC) of calcium flux on Ba/F3-FcγRI cells upon antibody binding and crosslinking with secondary antibody. M22 and H22 were used as positive controls. n Superoxide by IFN-γ-stimulated neutrophils in relative light units (RLU). Lines show the average of N = 3 measurements in triplicate for m22 and H22, and N = 6 for mAb 197, C01, C04, and 10.1. o AUC of superoxide, including baseline release (PBS), is indicated by a dotted line. Ordinary one-way ANOVA, with Tukey multiple comparison test. All line and bar data are presented as mean ± SEM. Source data are provided as a Source Data file.
Data sourced from citation (PMID: 41258113)
Flow Cytometry

Fab- and Fc-mediated binding of representative mAb H22 to hFcγRI. Binding of H22 (Fc-functional) and H22FcX (Fc-silent) to wild-type human FcγRI and chimeric domain swap constructs was assessed by flow cytometry. m22 (mIgG1, Fc-silent) and hIgG1 were included as Fab-only and isotype controls, respectively. Data demonstrate that Fab-mediated binding to EC1 is preserved in the absence of Fc engagement, highlighting EC1 as the primary epitope for variable region recognition.
Data sourced from citation (PMID: 41146600)
Bioactivity

(d) Direct crosslinking of C01 and C04 with a goat anti-human IgG. C01 and C04 were added during the dye incubation. H22 (dark green) was taken along as positive control.
Data sourced from citation (PMID: 41258113)

Extracellular domain 1 of human FcγRI (CD64) identified as the binding site for anti-FcγRI antibodies. [FHC93420]

Preclinical assessment of two FcγRI-specific antibodies that competitively inhibit immune complex-FcγRI binding to suppress autoimmune responses. [FHC93420]

Glial reactivity and T cell infiltration in frontotemporal lobar degeneration with tau pathology., PMID:37703311

The solution structure of the unbound IgG Fc receptor CD64 resembles its crystal structure: Implications for function., PMID:37733670

Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis., PMID:37792857

Repurposing Fc gamma receptor I (FcγRI, CD64) for site-oriented monoclonal antibody capture: A proof-of-concept study for real-time detection of tumor necrosis factor-alpha (TNF -α)., PMID:37809995

High levels of PD-L1 on platelets of NSCLC patients contributes to the pharmacological activity of Atezolizumab., PMID:37857253

Adaptive design of mRNA-loaded extracellular vesicles for targeted immunotherapy of cancer., PMID:37857647

Dual targeted extracellular vesicles regulate oncogenic genes in advanced pancreatic cancer., PMID:37872156

Synthetic immune checkpoint engagers protect HLA-deficient iPSCs and derivatives from innate immune cell cytotoxicity., PMID:37922880

Associations of myeloid cells with cellular and humoral responses following vaccinations in patients with neuroimmunological diseases., PMID:38007484

iPSC-derived natural killer cells expressing the FcγR fusion CD64/16A can be armed with antibodies for multitumor antigen targeting., PMID:38056893

FLAER as a standalone reagent for paroxysmal nocturnal hemoglobinuria: Do we need to reconsider the guidelines for testing?, PMID:38069562

Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors., PMID:38077405

iPSC-derived natural killer cells expressing the fcγr fusion CD64/16A can be armed with antibodies for multitumor antigen targeting., PMID:38154859

Antiviral and Anti-Inflammatory Therapeutic Effect of RAGE-Ig Protein against Multiple SARS-CoV-2 Variants of Concern Demonstrated in K18-hACE2 Mouse and Syrian Golden Hamster Models., PMID:38180084

Fc-gamma receptor expression and cytokine responses to intravenous human immunoglobulin in whole blood from non-pregnant and pregnant women and newborns., PMID:38180331

Anti-CD64 Antibody-Conjugated PLGA Nanoparticles Containing Methotrexate and Gold for Theranostics Application in Rheumatoid Arthritis., PMID:38267687

MRI and Blood-based Biomarkers Are Associated With Surgery in Children and Adults With Ileal Crohn's Disease., PMID:38738296

Druggability properties of a L309K mutation in the antibody CH2 domain., PMID:38742229

Invasive and Non-invasive Clinical Haemophilus influenzae Type A Isolates Activate Differentiated HL-60 Cells In Vitro., PMID:38774126

ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for in vivo efficacy against SARS-CoV-2., PMID:38948747

iPSC-derived NK cells expressing high-affinity IgG Fc receptor fusion CD64/16A to mediate flexible, multi-tumor antigen targeting for lymphoma., PMID:39100677

Production and characterization of novel Anti-HIV Fc-fusion proteins in plant-based systems: Nicotiana benthamiana & tobacco BY-2 cell suspension., PMID:39142626

Suppressing anti-citrullinated protein antibody-induced osteoclastogenesis in rheumatoid arthritis using anti-CD64 and PAD-2 inhibitors., PMID:39152765

CD64+ fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8+ T cells., PMID:39187291

Systematic analysis of Fc mutations designed to reduce binding to Fc-gamma receptors., PMID:39279104

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors., PMID:39306747

Decreased NETosis-related regulators in neuromyelitis optica spectrum disorders after plasma exchange., PMID:39321705

Affinity-based 3D-printed microfluidic chip for clinical sepsis detection with CD69, CD64, and CD25., PMID:39383543

The contribution of the CRP/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages., PMID:39564003

ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma., PMID:39596506

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies., PMID:39706209

Identification of the linear Fc-binding epitope on the bovine IgG1 Fc receptor of (boFcγRI) using synthetic peptides., PMID:39746504

Construction and characterization of chimeric FcγR T cells for universal T cell therapy., PMID:39810257

Antibody-Dependent Cellular Cytotoxicity of iPS Cell-Derived Natural Killer T Cells by Anti-GD2 mAb for Neuroblastoma., PMID:39916425

BNT162b2 mRNA vaccination affects the gut microbiome composition of patients with follicular lymphoma and chronic lymphocytic leukemia., PMID:39930533

The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity., PMID:39962623

Integrating early response biomarkers in pharmacokinetic models: A novel method to individualize the initial infliximab dose in patients with Crohn's disease., PMID:39985779

Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer., PMID:40051118

Gene-modified NK cells expressing CD64 and preloaded with HIV-specific BNAbs target autologous HIV-1-infected CD4+ T cells by ADCC., PMID:40073240

Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen., PMID:40096254

Anti-CD64(scFv)-SNAP-Auristatin F: An in vitro proof of concept study for a recombinant antibody conjugate targeting CD64+ acute monocytic leukemia., PMID:40112664

Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling., PMID:40145093

Combining CD64 and CD123 Biomarkers for Sepsis Early Diagnosis and Severity Assessment via PD-L1 Antibody Affinity Microfluidic (PAAM) Chip in Trace Clinical Samples., PMID:40177943

Macrophage requirements for abatacept response in rheumatoid arthritis., PMID:40242906

Immune Landscape Variation in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Circulation Before and After Plasmapheresis by Single-Cell Transcriptome., PMID:40256686

Neutrophil Z Is a Novel Marker to Differentiate Disease Flares From Bacterial Infections in Febrile SLE Patients., PMID:40302194

Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947

Effects of ulinastatin on therapeutic outcomes and inflammatory markers in pediatric septic shock patients., PMID:40360546

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?, PMID:40394835

Human Fcγ-receptors selectively respond to C-reactive protein isoforms., PMID:40458392

Document Download

Anti-Human CD64/FCGR1A Antibody (MDX-33).pdf

Anti-Human CD64/FCGR1A Antibody (MDX-33)